Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials

@article{Qi2013PaclitaxelbasedVD,
  title={Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials},
  author={Wei-xiang Qi and Zan Shen and Feng Lin and Yuan-jue Sun and Daliu Min and Lina Tang and Ai-na He and Yang Yao},
  journal={Current Medical Research and Opinion},
  year={2013},
  volume={29},
  pages={117 - 125}
}
  • W. Qi, Zan Shen, Yang Yao
  • Published 1 February 2013
  • Medicine
  • Current Medical Research and Opinion
Abstract Objectives: Docetaxel and paclitaxel show significant clinical activity in metastatic breast cancer (MBC) and have been approved for MBC by the U.S. Food and Drug Administration, but it is still unclear whether a paclitaxel-based regimen improves outcomes over a docetaxel-based regimen in patients with MBC. We therefore performed a meta-analysis of randomized controlled trials to compare the safety and efficacy of these two regimens in MBC. Methods: We systematically searched for… 
Role of nab-paclitaxel in metastatic breast cancer: a meta-analysis of randomized clinical trials.
TLDR
The newer agent was associated with increased sensory neuropathy, equivalent survival, and possibly increased overall response for some specific patients, and this meta-analysis failed to demonstrate advantages of nab-pac Litaxel compared with sb-paclitaxel and docetaxel in patients with MBC.
Taxane-containing regimens for metastatic breast cancer.
TLDR
Comparing taxane-containing chemotherapy regimens with regimens not containing a taxane in the management of women with metastatic breast cancer found taxanes were associated with an increased risk of neurotoxicity and hair loss with moderate to substantial heterogeneity across trials.
A Meta-Analysis of the Efficacy of Albumin Paclitaxel versus Docetaxel in the Treatment of Breast Cancer
TLDR
Meta-analysis results showed that albumin paclitaxel treatment can better reduce the incidence of neutropenia in breast cancer patients and is of great significance to the safety of cancer patients.
Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study
TLDR
Weekly carboplatin–paclitaxel regimen is active and well tolerated in mBC treatment, and Prospective studies should be conducted to compare its efficacy and tolerability with standard single-agent pac litaxel or docetaxel treatment schedules, as well as with more recent combination regimens.
Paclitaxel-based regimens as first-line treatment in advanced gastric cancer
TLDR
The paclitaxel-based regimens appeared to be effective in patients with advanced gastric cancer, and the triplet regimen produced a higher response rate than either doublet regimen with more side effects, while survivals were similar among all three treatments.
Efficacy of paclitaxel-based doublet regimens combining with intraperitoneal chemotherapy for advanced gastric cancer with peritoneal metastasis.
TLDR
Paclitaxel-based doublet regimens combining with IPC is effective, feasible and tolerated in AGC patients with PM, and the ECOG PS and IVC±IPC were independent prognostic factors for PFS and OS.
A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer
TLDR
The combination of EXE/EVE as first- or second-line therapy for ER+ve/HER2−ve metastatic breast cancer is more efficacious than several chemotherapy regimens that were reported in the literature.
Combination chemotherapy with paclitaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer
TLDR
Combination chemotherapy with PTX and OXA offers a new, effective and safe regimen for patients with advanced gastric cancer, and this study is a retrospective analysis evaluating the efficacy and toxicity.
Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer
TLDR
The present review summarizes the principal clinical trials evaluating the efficacy of taxanes both as monotherapy and in combination in view of the potential use in the treatment of PDAC.
Risk factors for the development of hematological toxicity during the application of weekly paclitaxel in breast cancer
TLDR
The low incidence of grade III-IV neutropenia in daily clinical practice during weekly paclitaxel suggests a reconsideration of the weekly evaluation with blood biometry in patients without risk factors.
...
1
2
3
...

References

SHOWING 1-10 OF 40 REFERENCES
A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study
TLDR
In this study, paclitaxel or docetaxel combined with doxorubicin were not significantly different in terms of QoL scores and efficacy, but had different toxicity profiles.
A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer
TLDR
Pw appears to be the most preferable choice among the 3 anthracycline-free taxanes-based regimens tested in the present study, and cost analysis favored Pw.
Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.
  • W. Gradishar, D. Krasnojon, P. Bhar
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
TLDR
This phase II study examined the antitumor activity and safety of weekly and every 3 week nab-paclitaxel compared with docetaxel as first-line treatment in patients with MBC and demonstrated superior efficacy and safety.
Paclitaxel and docetaxel in the treatment of breast cancer.
TLDR
Clinicians should choose a taxane-based regimen for their patients, according to clinical activity, toxicity profile, pharmacokinetics, and a dosing schedule that best meets the therapeutic needs and convenience, based on existing evidence.
Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer.
  • S. Jones, J. Erban, P. Ravdin
  • Medicine, Chemistry
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
TLDR
Docetaxel was superior to paclitaxel in terms of OS and TTP and the overall response rate (ORR) was higher for docetaxe than for pac litaxel.
Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342.
  • E. Winer, D. Berry, L. Norton
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
TLDR
Higher doses of paclitaxel administered as a 3-hour infusion to women with metastatic breast cancer did not improve response rate, survival, or quality of life, but there was a slight improvement in time to progression with higher dose therapy, which was offset by greater toxicity.
Bi-weekly docetaxel and gemcitabine regimen in her-2-negative and anthracycline-pretreated metastatic breast cancer patients: a multicenter phase II trial
TLDR
The GD bi-weekly regimen is well tolerated and active as first line in anthracyclines-pretreated women with MBC, and appears as an interesting alternative compared to a 3-week schedule whenever hematological toxicity is the main clinical concern.
...
1
2
3
4
...